<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Evaluation of C-terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-10-27">27 October 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Nadja</forename><surname>Scherbakov</surname></persName>
							<affiliation key="aff1">
								<orgName type="laboratory">German Centre for Cardiovascular Research (DZHK)</orgName>
								<address>
									<addrLine>partner site Berlin</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Knops</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Nicole</forename><surname>Ebner</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medicine Göttingen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Miroslava</forename><surname>Valentova</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medicine Göttingen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">1st Department of Internal Medicine</orgName>
								<orgName type="institution">Comenius University</orgName>
								<address>
									<settlement>Bratislava</settlement>
									<country key="SK">Slovak Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anja</forename><surname>Sandek</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medicine Göttingen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulrike</forename><surname>Grittner</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pius</forename><surname>Dahinden</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">Neurotune AG</orgName>
								<address>
									<addrLine>Wagistrasse 27a</addrLine>
									<settlement>Schlieren</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Hettwer</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">Neurotune AG</orgName>
								<address>
									<addrLine>Wagistrasse 27a</addrLine>
									<settlement>Schlieren</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jörg</forename><forename type="middle">C</forename><surname>Schefold</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Intensive Care Medicine</orgName>
								<orgName type="institution">University Hospital of Bern</orgName>
								<address>
									<settlement>Inselspital</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephan</forename><surname>Von Haehling</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medicine Göttingen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medicine Göttingen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Joebges</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Neurology, Brandenburgklinik Bernau</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Wolfram</forename><surname>Doehner</surname></persName>
							<email>wolfram.doehner@charite.de</email>
							<affiliation key="aff1">
								<orgName type="laboratory">German Centre for Cardiovascular Research (DZHK)</orgName>
								<address>
									<addrLine>partner site Berlin</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Charite Universitätsmedizin Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Center for Stroke Research CSB</orgName>
								<orgName type="institution">Charite Universitätsmedizin Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department">Center for Stroke Research Berlin</orgName>
								<orgName type="institution">Charite Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Evaluation of C-terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-10-27">27 October 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">A00D50BFC038EA8A949EED372C915F6E</idno>
					<idno type="DOI">10.1002/jcsm.12068</idno>
					<note type="submission">Received: 5 August 2014; Revised: 15 July 2015; Accepted: 31 July 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:35+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Stroke</term>
					<term>Muscle wasting</term>
					<term>Post-stroke rehabilitation</term>
					<term>C-terminal Agrin Fragment</term>
					<term>Physical performance</term>
					<term>Skeletal muscle mass</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background C-terminal Agrin Fragment (CAF) has been proposed as a novel biomarker for sarcopenia originating from the degeneration of the neuromuscular junctions.</s><s>In patients with stroke muscle wasting is a common observation that predicts functional outcome.</s><s>We aimed to evaluate agrin sub-fragment CAF22 as a marker of decreased muscle mass and physical performance in the early phase after acute stroke.</s></p><p><s>Methods Patients with acute ischaemic or haemorrhagic stroke (n = 123, mean age 70 ± 11 y, body mass index BMI 27.0 ± 4.9 kg/m 2 ) admitted to inpatient rehabilitation were studied in comparison to 26 healthy controls of similar age and BMI.</s><s>Functional assessments were performed at begin (23 ± 17 days post stroke) and at the end of the structured rehabilitation programme (49 ± 18 days post stroke) that included physical assessment, maximum hand grip strength, Rivermead motor assessment, and Barthel index.</s><s>Body composition was assessed by bioelectrical impedance analysis (BIA).</s><s>Serum levels of CAF22 were measured by ELISA.</s></p><p><s>Results CAF22 levels were elevated in stroke patients at admission (134.3 ± 52.3 pM) and showed incomplete recovery until discharge (118.2 ± 42.7 pM) compared to healthy controls (95.7 ± 31.8 pM, p &lt; 0.001).</s><s>Simple regression analyses revealed an association between CAF22 levels and parameters of physical performance, hand grip strength, and phase angle, a BIA derived measure of the muscle cellular integrity.</s><s>Improvement of the handgrip strength of the paretic arm during rehabilitation was independently related to the recovery of CAF22 serum levels only in those patients who showed increased lean mass during the rehabilitation.</s></p><p><s>Conclusions CAF22 serum profiles showed a dynamic elevation and recovery in the subacute phase after acute stroke.</s><s>Further studies are needed to explore the potential of CAF22 as a serum marker to monitor the muscle status in patients after stroke.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Skeletal muscle wasting has been frequently observed after stroke. <ref type="bibr" target="#b0">1</ref> Already within 4 h after cerebral damage an initial reduction of motoneurons in the musculature of paretic limb is observed 2 that persists in the chronic phase after stroke. <ref type="bibr" target="#b2">3</ref></s><s>oss of muscle innervation leads to muscular weakness, inactivity, and immobilization and results in muscle atrophy.</s></p><p><s>Within the first week after stroke muscle weakness occurs also in the non-paretic limb. <ref type="bibr" target="#b3">4</ref></s><s>Decline of muscle mass has been observed in stroke patients within first three weeks after hemiparetic stroke. <ref type="bibr" target="#b4">5</ref></s><s>Further, patients who are not able to relearn walking within 2 months after stroke revealed similar lean mass reduction in paretic and non-paretic leg. <ref type="bibr" target="#b5">6</ref></s><s>A combination of mechanisms, including immobilization, disuse, inflammation, metabolic, and neurovegetative imbalance after stroke, results frequently in muscle wasting and may progress to the stroke-related sarcopenia. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b6">7</ref></s><s>The presence of stroke-specific sarcopenia has been proposed from experimental <ref type="bibr" target="#b7">8</ref> and clinical data. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b9">10</ref></s><s>rogressive degradation of muscle mass was termed as 'sarcopenia' and was originally observed in relationship to aging. <ref type="bibr" target="#b10">11</ref></s><s>The prevalence of sarcopenia is about 5 to 10% in persons over 65 years of age. <ref type="bibr" target="#b11">12</ref></s><s>]<ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref> In aging loss of motoneurons has been proposed as pathogenic and contributing to the developing of sarcopenia. <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20</ref></s><s>ecently, C-terminal Agrin Fragment (CAF) has been proposed as a potential marker for sarcopenia caused by degeneration of the neuromuscular junctions (NMJs) in elderly. <ref type="bibr" target="#b20">21</ref></s><s>grin is a heparin sulphate proteoglycan with a molecular weight of 225 kDa, which is considered as a key organizer of postsynaptic differentiation at NMJs. <ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref> Proper clustering of acetylcholine receptors (AChR) at post-synaptic basal lamina depends on agrin-mediated signalling. <ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b24">25</ref></s><s>Proteolytic cleavage of agrin by neuronal protease neurotrypsin at NMJs triggers inactivation and destabilization of the NMJ with subsequent muscle degradation.</s><s>A sarcopenic phenotype has been observed in transgenic mouse with neurotrypsin overexpression. <ref type="bibr" target="#b25">26</ref></s><s>In human plasma two stable and bio-inactive circulating fragments of agrin-AgrinC110 (cleavage at α-site) and CAF22 (cleavage at β-site) were identified (Figure <ref type="figure" target="#fig_0">1</ref>). <ref type="bibr" target="#b20">21</ref></s><s>It has been shown that elevated CAF22 plasma levels may indicate muscle wasting in pre-frail community-dwelling older adults because of degeneration of the NMJ. <ref type="bibr" target="#b26">27</ref></s><s>The reduction of CAF22 levels after 12 week power training supports CAF22 as a marker of muscle wasting and the development of sarcopenia.</s><s>In contrast, a study evaluating an effect of resistance training in older adults revealed elevation of CAF levels following 6-weeks of training. <ref type="bibr" target="#b27">28</ref></s><s>e aim of the present study was to evaluate agrin as a marker of muscle wasting in patients with stroke.</s><s>Because physical exercise is an effective therapy to prevent muscle wasting, <ref type="bibr" target="#b29">29</ref> we investigated a cohort of stroke patients in the early post stroke rehabilitation.</s><s>We hypothesized that CAF22 might be a marker of muscle status and function during recovery after paretic stroke.</s><s>We evaluated CAF22 in relation to changes in muscle mass and functional recovery during early rehabilitation period.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population and enrolment criteria</head><p><s>We studied 123 patients (age ranging from 42 to 98 years) with confirmed diagnosis of ischaemic or haemorrhagic stroke.</s><s>Patients were admitted from October 2011 to August 2013 to neurological rehabilitation centre Brandenburgklinik Bernau, Germany.</s><s>Clinical and functional examinations were performed at admission and at discharge.</s><s>Within the early post-stroke hospitalized rehabilitation programme all patients were on standard medical therapy according to current guideline recommendations (including antiplatelet drugs, statins, angiotensin-converting enzyme inhibitors, and β-blocker).</s><s>Exclusion criteria for this observational study were acute and chronic inflammatory diseases, acute heart failure or myocardial infarction, liver cirrhosis, acute and chronic renal failure and dialysis, immune suppressive therapy, and history of cancer within the last 5 years.</s><s>Twenty six healthy individuals of similar body mass index (BMI) and age were enrolled used as control group.</s><s>The research protocol was approved by the local ethics committee, and written informed consent was obtained from all subjects.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessment of functional capacity and physical examination</head><p><s>Functional independence was assessed using the Barthel index (BI) that addresses basic self-care and mobility aspects with a score ranging from 0 to 100, where the lowest score indicates greater dependency. <ref type="bibr" target="#b30">30</ref></s><s>Assessment of physical status included following testing: the Rivermead motor assessment gross function subscale (RMA) that scores a range of physical activities with increasing complexity from turning over in bed to hop on the affected leg 5 times. <ref type="bibr" target="#b31">31,</ref><ref type="bibr" target="#b32">32</ref></s><s>Arm strength was analysed using the handgrip dynamometer (Saehan Corporation, Korea).</s><s>The highest of three handgrip measurements was used for analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Body composition</head><p><s>Body mass index (BMI) was calculated as a ratio of body weight and squared height (kg/m 2 ).</s><s>Body composition was assessed by bioelectrical impedance analysis (BIA) (QuadScan 4000, Bodystat Limited, UK).</s><s>The principle of BIA analyses is based on measurements of whole body resistance (R) and reactance (Xc) values <ref type="bibr" target="#b33">33</ref> where R reflects conductivity through ionic solutions, and Xc reflects dielectric properties of plasma membrane measured as a phase-shift in current flow at 50 Hz.</s><s>Phase angle of the whole body (ϕ, arc tangent expressing a relationship between Xc and R) is understood as bioimpedance measures of cell membranes of skeletal muscle and as indicator of cellular health. <ref type="bibr" target="#b34">34</ref></s><s>BIA measurements were taken in supine position in standard condition as described previously. <ref type="bibr" target="#b35">35</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Blood samples</head><p><s>Venous blood samples were obtained under standardized conditions after overnight fasting and after 15 min of supine resting in a quiet and air conditioned room.</s><s>Samples were centrifuged at 3500 rpm for 15 min (2000x g), aliquoted and stored at À80°C until analysis.</s><s>CAF22 concentrations were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (NTCAF Elisa Kit; Neurotune, Schieren, Switzerland) as described previously. <ref type="bibr">36</ref></s><s>The coefficient of variance of the test is 12.3% maximal deviation for serum and 5.6% maximal deviation for the used calibrator in a combined intra-and inter-plate comparison.</s><s>For the tested samples, the deviation must have been lower than 20% in each double measurement.</s><s>The accuracy of the calibrator curve was &gt;0.98 (Rsqr), and the validated range of detection was 20 pM to 380 pM.</s><s>In case of higher CFA values, the sample was diluted with PBS and remeasured until the value was within the detection range.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>All variables were tested for normal distribution using the Kolmogorov-Smirnov test.</s><s>All data were presented as mean values ± standard deviation or as median [interquartile range, IQR].</s><s>Paired Student t-test, unpaired Student t-test, and Mann-Whitney test were used as appropriate.</s><s>Chi Square test was used to assess categorical distribution between groups.</s><s>The relationship between variables was analysed by linear and multiple regression analyses.</s><s>A value of p &lt; 0.05 was considered statistically significant.</s><s>For statistical analysis, standard statistical software packages were used (Statview 5.0, SAS Institute, Cary, NC).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical and functional characteristics before and after rehabilitation</head><p><s>Functional assessments were performed at admission (23 ± 17 days post stroke) and at discharge from the rehabilitation centre (49 ± 18 days post stroke).</s></p><p><s>Baseline characteristics of study population groups are shown in Table <ref type="table" target="#tab_0">1</ref>.</s><s>Patients and healthy controls were of similar age and body mass index (BMI).</s><s>Fifty-five per cent of the stroke patients revealed a 2.2% increase of the lean mass at discharge, whereas in the rest of the patients revealed a decline of the body lean mass by 2.6% (Table <ref type="table" target="#tab_1">2</ref>).</s><s>Physical performance and muscle functional measures were significantly impaired after stroke compared to controls (data shown for the hand grip strength, Figure <ref type="figure">2</ref>) and improved during rehabilitation as assessed by maximum hand grip strength, Barthel index, and Rivermead motor assessment (Table <ref type="table" target="#tab_1">2</ref>).</s><s>Thus, patients presented better functional performance at discharge from the rehabilitation centre compared to admission.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CAF22 plasma level during rehabilitation</head><p><s>At admission, CAF22 serum level was significantly elevated (+26%) in stroke patients compared to controls (p &lt; 0.001, unpaired t-test; Figure <ref type="figure" target="#fig_1">3A</ref>).</s><s>CAF22 level declined subsequently during rehabilitation but remained 17% above the control group at discharge (p &lt; 0.05; Figure <ref type="figure" target="#fig_1">3A</ref>).</s><s>The mean change of CAF22 serum level between discharge and admission was expressed as a change of total CAF22 (Table <ref type="table" target="#tab_0">1</ref>).</s><s>CAF22 serum levels were not significantly different in females compared to male patients (Table <ref type="table" target="#tab_0">1</ref>).</s><s>However, compared to healthy controls female stroke patients showed 21% higher CAF22 level at admission (Figure <ref type="figure" target="#fig_1">3B</ref>), whereas between male patients and controls this difference was 56% (Figure <ref type="figure" target="#fig_1">3C</ref>).</s><s>At discharge, CAF22 was 12% higher in female but still 41% higher in male patients compared to controls of the same gender.</s><s>Thus, CAF22 level rise after stroke seems to be more pronounced in male than in female patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CAF22 and functional performance</head><p><s>In the linear regression analyses CAF22 levels were associated with BI (r = 0.2, p &lt; 0.022), RMA score (r = 0.2, p &lt; 0.05), hand grip strength of the non-paretic arm (r = 0.2, p &lt; 0.05), age (r = 0.4, p &lt; 0.001), and creatinine levels (r = 0.7, p &lt; 0.001).</s></p><p><s>In multivariable regression analyses change of CAF22 serum level was independently associated with improvement of the hand grip strength of the paretic arm, but not in the non-paretic arm in patients who showed increased muscle mass during rehabilitation (Table <ref type="table" target="#tab_4">3B</ref>).</s><s>However, this association was not observed in the whole study cohort (Table <ref type="table" target="#tab_4">3A</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CAF22 levels and phase angle</head><p><s>A strong association between CAF22 level at admission and phase angle (r = À0.351,</s><s>p &lt; 0.001) was observed in simple regression analysis.</s><s>After adjustment for age, creatinine level, and gender this association remained independently significant (Table <ref type="table" target="#tab_3">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The major finding of the study is the elevation and dynamic change of CAF22 serum levels in patients after acute stroke.</s><s>CAF22 serum levels were significantly increased in the subacute phase after stroke.</s><s>During rehabilitation, an incomplete return of elevated CAF22 levels was observed.</s><s>CAF22 was associated with parameters of physical and functional performance and with bioelectrical impedance phase angle.</s><s>Further, an improvement of hand grip strength of the paretic arm during rehabilitation was independently associated with the reduction of CAF22 serum levels in patients who showed an increase of muscle mass during rehabilitation.</s><s>We observed elevated CAF22 serum levels at admission to inpatient rehabilitation.</s><s>CAF22 levels decreased during 4 weeks of a rehabilitation programme but were still higher at discharge compared to healthy subjects.</s><s>Our findings are in line with previous reports showing a reduction of elevated CAF22 levels after a training programme in a cohort of elder subjects. <ref type="bibr" target="#b26">27</ref></s><s>These authors suggested CAF22 as a potential marker of age-associated sarcopenia caused by the degeneration of the NMJ.</s><s>In our study patients were admitted to the rehabilitation hospital 3 weeks after stroke.</s><s>At this time point patients revealed significantly reduced handgrip strength in parallel to elevated CAF22 serum levels.</s><s>In addition, our analyses have shown an independent association between reduction of CAF22 serum levels and improvement of hand grip strength of the paretic arm in patients with increased muscle mass during rehabilitation.</s><s>Decreasing of CAF22 levels after 4 weeks of a physical rehabilitation programme might therefore suggest termination of the muscle wasting and reactive NMJs recovery.</s></p><p><s>Recently, CAF22 has been evaluated as a biomarker of kidney function.</s><s>Indeed, agrin is expressed in the kidney and CAF22 has been related to the damage of the glomerular basement membrane. <ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b37">38</ref></s><s>In our study patients with renal failure as well as with dialysis were excluded.</s><s>We observed a strong correlation between CAF22 and creatinine, although the reduction of the creatinine serum level at discharge was not significant in contrast to the significant reduction of the CAF22 serum levels.</s><s>Thus, it is not clear to which extent CAF22 serum levels reflect the kidney function in stroke patients.</s><s>Yet, a confounder for CAF22 serum levels because of kidney function could not be excluded and may be seen as a limitation of the study.</s></p><p><s>In addition, the existence of several splicing isoforms of agrin should be considered in the evaluation of CAF22 as a biomarker for sarcopenia. <ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b38">39</ref></s><s>Agrin function is highly regulated by alternative splicing and proteolytic processing.</s><s>Splicing isoforms containing 0 or 4 amino acid inserts at the y splicing site of the LG2 domain and 0, 8, 11, or 19 (8 + 11)  amino acid inserts at the z splicing site of the LG3 domain of the C-terminus have been investigated (Figure <ref type="figure" target="#fig_0">1</ref>). <ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b39">40</ref></s><s>he neural agrin containing 4 and 8 amino acid inserts at the y and z sites, respectively, has a high affinity to the AChR clustering, while muscle agrin and agrin found in other nonneuronal cells lacks inserts and fails to cluster AChRs. <ref type="bibr" target="#b40">41</ref></s><s>However, splicing isoforms of agrin lacking inserts have been found in NMJs (motor neurons, skeletal muscle, and Schwann cells), in the central nervous system and peripheral tissues (lung and kidney). <ref type="bibr" target="#b22">23</ref></s><s>The ELISA assay used in the present study predominately identifies the z0 splicing isoform.</s><s>Previous experiments have shown that the z0 splicing isoform is at least 10-20 folds overrepresented over the insert baring</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>B C</head><p><s>splice isoforms (Western blots and internal analyses).</s><s>The appearance of the z0 splicing variant of the C-terminal agrin fragments in blood, however, represents the activity of neurotrypsin. <ref type="bibr" target="#b41">42</ref></s><s>Further, a vast amount of z0 isoform of agrin is present on the postsynaptic side, which is also cleavable by neurotrypsin.</s><s>Muscle agrin is concentrated at the nerveinduced AChR clusters where it contributes to maturation and stabilization of the receptors. <ref type="bibr" target="#b42">43,</ref><ref type="bibr" target="#b43">44</ref></s><s>Therefore, the postsynaptic muscle agrin is able to liberate CAF22, which may then be secreted and may appear in the blood stream.</s><s>Thus, we believe that in stroke patients a significant amount of the CAF22 in serum origins from the nervous tissue or postsynaptic tissue because of denervation and degradation of the NMJs.</s><s>However, optimization of the ELISA assay towards identifying of the neuronal agrin might improve the specificity and sensitivity of the results and may contribute to the establishing of CAF22 as a marker of muscle wasting caused by NMJ degeneration.</s></p><p><s>Our analyses revealed an independent association of the BIA phase angle with CAF22 levels.</s><s>Phase angle has been shown in relation to the muscle mass and muscle strength; therefore phase angle represents a simple index of the integrity of the skeletal muscle cell membranes. <ref type="bibr" target="#b34">34</ref></s><s>A previous study in patients with neuromuscular diseases has shown a decline of phase angle in parallel with disease progression that was accompanied by a subsequent decline of muscle strength and quality of muscle tissue. <ref type="bibr" target="#b44">45</ref></s><s>Therefore our data suggest lower CAF22 to indicate a better cellular integrity of muscle tissue.</s></p><p><s>The present study had same limitations.</s><s>As mentioned above, renal function may be a relevant confounder of CAF 22 levels.</s><s>Further, BIA assessment may provide only limited information on body composition and more detailed information on tissue distribution and composition may be desirable.</s><s>7]<ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref><ref type="bibr" target="#b49">[50]</ref> Another study examining muscle mass assessed by BIA and MRI indicated a strong relation between muscle mass and body resistance. <ref type="bibr" target="#b48">49</ref></s><s>owever, underestimation of the fat mass and over predicting of the fat-free mass assessed by BIA has been reported. <ref type="bibr" target="#b46">47</ref></s><s>In addition, the presence of oedema may influence BIA measurements.</s><s>The effect of the whole body water changes and its dependence from the sodium plasma concentrations has been discussed previously. <ref type="bibr" target="#b50">51</ref></s><s>However, in the present study patients were free of peripheral oedema and sodium plasma levels remained unchanged suggesting stable fluid balance during the observation period.</s></p><p><s>In conclusion, CAF22 serum levels were elevated in the subacute phase after acute stroke and fell during rehabilitation.</s><s>Associations between CAF22 and parameters of physical performance, muscle strength, and muscle membrane integrity have been observed.</s><s>In multivariable analysis recovery of increased CAF22 levels was independently associated with improved hand grip strength only in those patients who showed increasing lean tissue during rehabilitation but not in the entire cohort.</s><s>The present data are promising to explore further the role CAF22 as a potential serum marker for monitoring muscle status in patients after stroke.</s><s>Further studies are warranted including optimization of the analytic assay of CAF to evaluate the role of CAF22 as a serum marker of muscle wasting in stroke patients.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Structure and cleavage sites of agrin.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure3CAF22 plasma level in stroke-patients at admission to rehabilitation centre and at discharge compared to controls: All patients (A); Female patients (B); Male patients (C) (***p &lt; 0.001, **p &lt; 0.01, *p &lt; 0.05 vs. controls; ### p &lt; 0.001 vs. admission).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Clinical characteristics of study groups</s></p></div></figDesc><table><row><cell>Parameters</cell><cell>Controls n = 26</cell><cell>Patients at admission n = 123</cell><cell>Patients at discharge n = 123</cell></row><row><cell>Age, y</cell><cell>67 ± 8</cell><cell>70 ± 11</cell><cell>70 ± 11</cell></row><row><cell>Gender, f/m [m, %]</cell><cell>17/9 [41]</cell><cell>49/74 [60]*</cell><cell></cell></row><row><cell>Stroke ischaemic, n [%] / haemorrhagic, n [%] Days after stroke CAF22, pMol CAF22, pMol, female CAP22, pMol, male</cell><cell>95.7 ± 31.8 102.6 ± 30.7 82.7 ± 31.2</cell><cell>106 [86] / 17 [16] 23 ± 17 134.3 ± 52.3*** 140.3 ± 51.6** 130.2 ± 52.7**</cell><cell>49 ± 18 ### 118.2 ± 42.7* ### 119.5 ± 35.5 ### 117.3 ± 47.1* ###</cell></row><row><cell>Change of total CAF22, pMol</cell><cell></cell><cell></cell><cell>À16.1 ± 30.4</cell></row><row><cell>Creatinine, mg/dL</cell><cell>0.79 ± 0.14</cell><cell>0.97 ± 0.31**</cell><cell>0.96 ± 0.33</cell></row><row><cell>Sodium, mmol/L</cell><cell>141.5 ± 3.3</cell><cell>140.1 ± 4.4</cell><cell>140.3 ± 2.7</cell></row><row><cell>Potassium, mmol/L Body mass index, kg/m 2</cell><cell>4.4 ± 0.4 25.6 ± 3.3</cell><cell>4.4 ± 0.4 27.0 ± 4.9</cell><cell>4.3 ± 0.5 26.0 ± 5.2</cell></row><row><cell>Lean mass, kg</cell><cell>46.9 ± 10.1</cell><cell>51.9 ± 11.7*</cell><cell>51.6 ± 11.3</cell></row><row><cell>Fat mass, kg</cell><cell>24.9 ± 6.9</cell><cell>25.0 ± 9.7</cell><cell>23.4 ± 8.8</cell></row><row><cell>Phase angle, ϕ</cell><cell>5.7 ± 1.1</cell><cell>5.1 ± 1.0**</cell><cell>5.0 ± 1.0**</cell></row><row><cell>*p &lt; 0.05,</cell><cell></cell><cell></cell><cell></cell></row><row><cell>**p &lt; 0.01,</cell><cell></cell><cell></cell><cell></cell></row><row><cell>***p &lt; 0.001 vs. controls; ### p &lt; 0.001 vs. admission</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Parameters of body composition and physical performance at admission and at discharge from the rehabilitation centre</s></p></div></figDesc><table><row><cell></cell><cell>At admission</cell><cell>At discharge</cell></row><row><cell>Parameters</cell><cell>(n = 120)</cell><cell>(n = 120)</cell></row><row><cell>Lean mass increase,</cell><cell>50.6 ± 11.8</cell><cell>51.7 ± 11.7***</cell></row><row><cell>kg, n = 67</cell><cell></cell><cell></cell></row><row><cell>Lean mass decrease,</cell><cell>53.2 ± 11.7</cell><cell>51.7 ± 11.4***</cell></row><row><cell>kg, n = 56</cell><cell></cell><cell></cell></row><row><cell>Max hand grip</cell><cell>15.8 ± 11.6</cell><cell>16.0 ± 11.7***</cell></row><row><cell>strength paretic arm, kg</cell><cell></cell><cell></cell></row><row><cell>Max hand grip strength</cell><cell>28.2 ± 11.1</cell><cell>29.6 ± 11.7***</cell></row><row><cell>nonparetic arm, kg</cell><cell></cell><cell></cell></row><row><cell>Barthel Index score</cell><cell>60 ± 22</cell><cell>73 ± 20***</cell></row><row><cell>Rivermead Motor</cell><cell>5.3 ± 2.0</cell><cell>7.2 ± 2.2***</cell></row><row><cell>Assessment score</cell><cell></cell><cell></cell></row></table><note><p><s>***p &lt; 0.001 vs. admission Figure2Hand grip strength of stroke patients compared to healthy controls (***p &lt; 0.001 vs. controls; ### p &lt; 0.001 vs. admission).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 A</head><label>3</label><figDesc><div><p><s>).</s><s>Multiple regression analyses investigating change of hand grip strength during rehabilitation in stroke patients (n = 123)</s></p></div></figDesc><table><row><cell>Parameter</cell><cell>Coefficient</cell><cell>p</cell><cell>r</cell></row><row><cell>1. Change of hand grip strength of paretic arm vs.</cell><cell></cell><cell></cell><cell>0.286</cell></row><row><cell>Gender</cell><cell>0.059</cell><cell>0.579</cell><cell></cell></row><row><cell>Age</cell><cell>À0.229</cell><cell>0.035</cell><cell></cell></row><row><cell>Change of CAF22</cell><cell>À0.175</cell><cell>0.097</cell><cell></cell></row><row><cell>Creatinine</cell><cell>À0.102</cell><cell>0.353</cell><cell></cell></row><row><cell>2. Change of hand grip strength of nonparetic arm vs.</cell><cell></cell><cell></cell><cell>0.294</cell></row><row><cell>Gender</cell><cell>0.141</cell><cell>0.151</cell><cell></cell></row><row><cell>Age</cell><cell>À0.157</cell><cell>0.120</cell><cell></cell></row><row><cell>Change of CAF22</cell><cell>À0.121</cell><cell>0.223</cell><cell></cell></row><row><cell>Creatinine</cell><cell>À0.189</cell><cell>0.069</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc><div><p><s>Multiple regression analysis investigating phase angle as a parameter of cell membrane integrity in stroke patients</s></p></div></figDesc><table><row><cell>Parameter</cell><cell>Coefficient</cell><cell>p</cell><cell>r</cell></row><row><cell>Phase angle vs.</cell><cell></cell><cell></cell><cell>0.523</cell></row><row><cell>Gender</cell><cell>0.170</cell><cell>0.055</cell><cell></cell></row><row><cell>Age</cell><cell>À0.341</cell><cell>0.0003</cell><cell></cell></row><row><cell>Creatinine</cell><cell>0.095</cell><cell>0.422</cell><cell></cell></row><row><cell>CAF22</cell><cell>À0.267</cell><cell>0.026</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 3</head><label>3</label><figDesc><div><p><s>B.) Multiple regression analyses investigating changes in hand grip strength at discharge and admission in stroke patients with improved lean mass during rehabilitation (n = 67)</s></p></div></figDesc><table><row><cell>Parameter</cell><cell>Coefficient</cell><cell>p</cell><cell>r</cell></row><row><cell>1. Change of hand grip strength of paretic arm vs.</cell><cell></cell><cell></cell><cell>0.318</cell></row><row><cell>Gender</cell><cell>0.045</cell><cell>0.749</cell><cell></cell></row><row><cell>Age</cell><cell>À0.218</cell><cell>0.134</cell><cell></cell></row><row><cell>Change of CAF22</cell><cell>À0.292</cell><cell>0.045</cell><cell></cell></row><row><cell>Creatinine</cell><cell>À0.089</cell><cell>0.563</cell><cell></cell></row><row><cell>2. Change of hand grip strength of nonparetic arm vs.</cell><cell></cell><cell></cell><cell>0.301</cell></row><row><cell>Gender</cell><cell>0.046</cell><cell>0.723</cell><cell></cell></row><row><cell>Age</cell><cell>À0.100</cell><cell>0.465</cell><cell></cell></row><row><cell>Change of CAF22</cell><cell>À0.180</cell><cell>0.211</cell><cell></cell></row><row><cell>Creatinine</cell><cell>À0.293</cell><cell>0.055</cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Journal of Cachexia, Sarcopenia and Muscle 2016; 7: 60-67 DOI: 10.1002/jcsm.12068</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We thank Mrs. Anja Kresse for her excellent technical assistance with this study.</s><s>The authors certify that they comply with the ethical guidelines for authorship and publishing of the Journal of Cachexia, Sarcopenia and Muscle (von Haehling S, Morley JE, Coats AJS, Anker SD.</s><s>Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.</s><s>J Cachexia Sarcopenia Muscle.</s><s>2010; 1:7-8.)</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Stroke induced Sarcopenia: muscle wasting and disability after stroke</title>
		<author>
			<persName><forename type="first">N</forename><surname>Scherbakov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Dirnagl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">170</biblScope>
			<biblScope unit="page" from="89" to="94" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Reduction in the motor unit number estimate (MUNE) after cerebral infarction</title>
		<author>
			<persName><forename type="first">K</forename><surname>Arasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Igarashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ichikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Machida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Shirozu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hyodo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Sci</title>
		<imprint>
			<biblScope unit="volume">250</biblScope>
			<biblScope unit="page" from="27" to="32" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Power spectral analysis of surface electromyography (EMG) at matched contraction levels of the first dorsal interosseous muscle in stroke survivors</title>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Niu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Z</forename><surname>Rymer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Neurophysiol</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="988" to="994" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Quadriceps muscle weakness following acute hemiplegic stroke</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Polkey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Bath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moxham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Rehabil</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="274" to="281" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Longitudinal changes in muscle strength and mass after acute stroke</title>
		<author>
			<persName><forename type="first">Carin-Levy G</forename><surname>Greig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hannan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cerebrovasc Dis</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="201" to="207" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Changes in muscle mass, fat mass, and bone mineral content in the legs after stroke: a 1 year prospective study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Jørgensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Jacobsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="655" to="659" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Strokerelated Sarcopenia: specific characteristics</title>
		<author>
			<persName><forename type="first">N</forename><surname>Scherbakov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sandek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Med Dir Assoc</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="272" to="276" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Catabolic signaling and muscle wasting after acute ischemic stroke in mice: indication for a stroke-specific sarcopenia</title>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Peske</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rex</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stroke</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="3675" to="3683" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Muscle molecular phenotype after stroke is associated with gait speed</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>De Deyne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Hafer-Macko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Ivey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Macko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="209" to="215" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Sarcopenia in stroke-facts and numbers on muscle loss accounting for disability after stroke</title>
		<author>
			<persName><forename type="first">N</forename><surname>Scherbakov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="5" to="8" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Sarcopenia: origins and clinical relevance</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">H</forename><surname>Rosenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nutr</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="990S" to="991S" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="253" to="259" />
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wakabayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sakuma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="269" to="277" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Identifying recreational physical activities associated with muscle quality in men and women aged 50 years and over</title>
		<author>
			<persName><forename type="first">S</forename><surname>Barbat-Artigas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dupontgand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Pion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Feiter-Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Aubertin-Leheudre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="221" to="228" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Consensus definition of sarcopenia, cachexia and precachexia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Muscaritoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Argilés</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Aversa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Biolo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="154" to="159" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Molecular and cellular mechanisms of skeletal muscle atrophy: an update</title>
		<author>
			<persName><forename type="first">A</forename><surname>Fanzani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Conraads</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Penna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Martinet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="163" to="179" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Muscle wasting: an overview of recent developments in basic research</title>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="193" to="198" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Assessing sarcopenic prevalence and risk factors in residential aged care: methodology and feasibility</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Henwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Keogh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Reid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Jordan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Senior</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="229" to="236" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The Motor Unit Number Index (MUNIX) in sarcopenic patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Drey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Grösch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Neuwirth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Sieber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Gerontol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="381" to="384" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Sarcopenia: describing rather than defining a condition</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Alchin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="265" to="268" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hettwer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dahinden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kucsera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Farina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fariello</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Gerontol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="69" to="75" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">New insights into the roles of agrin</title>
		<author>
			<persName><forename type="first">G</forename><surname>Bezakova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Ruegg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="295" to="308" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Agrin orchestrates synaptic differentiation at the vertebrate neuromuscular junction</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Ruegg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Bixby</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Neurosci</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="22" to="27" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Molecular control of neuromuscular junction development</title>
		<author>
			<persName><forename type="first">E</forename><surname>Ferraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Molinari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Berghella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="13" to="23" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Structural mechanisms of the agrin-LRP4-MuSK signaling pathway in neuromuscular junction differentiation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jin</forename><forename type="middle">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Mol Life Sci</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="3077" to="3088" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Destabilization of the neuromuscular junction by proteolytic cleavage of agrin results in precocious sarcopenia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Bütikofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zurlinden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Bolliger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kunz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sonderegger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FASEB J</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="4378" to="4393" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">FiAT intervention group. C-terminal Agrin Fragment as a potential marker for sarcopenia caused by degeneration of the neuromuscular junction</title>
		<author>
			<persName><forename type="first">M</forename><surname>Drey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Sieber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Uter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dahinden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Fariello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Vrijbloed</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Gerontol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="76" to="80" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title level="m" type="main">Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Fragala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Jajtner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Beyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Townsend</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Emerson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Scanlon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hoffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Stout</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="139" to="148" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients?</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Rhee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kalantar-Zadeh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="177" to="180" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Clinical interpretation and use of stroke scales</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Kasner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Neurol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="603" to="612" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Assessment of motor function in stroke patients</title>
		<author>
			<persName><forename type="first">N</forename><surname>Lincoln</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Leadbitter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Physiotherapy</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="48" to="51" />
			<date type="published" when="1979">1979</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Collen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Wade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Robb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Bradshaw</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Disabil Stud</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="50" to="54" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Bioelectrical impedance analysis: a review of principles and applications</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Kushner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Nutr</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="199" to="209" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Norms and correlates of bioimpedance phase angle in healthy human subjects, hospitalized patients, and patients with liver cirrhosis</title>
		<author>
			<persName><forename type="first">O</forename><surname>Selberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Selberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Appl Physiol</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="509" to="516" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Assessment of fat-free mass using bioelectrical impedance measurements of the human body</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Lukaski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Bolonchuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">I</forename><surname>Lykken</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="810" to="817" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">C-terminal agrin fragment-a new fast biomarker for kidney function in renal transplant recipients</title>
		<author>
			<persName><forename type="first">D</forename><surname>Steubl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hettwer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Vrijbloed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dahinden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Luppa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Nephrol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="501" to="508" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Influence of high-flux hemodialysis and hemodiafiltration on serum C-terminal agrin fragment levels in end-stage renal disease patients</title>
		<author>
			<persName><forename type="first">D</forename><surname>Steubl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hettwer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dahinden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Luppa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Wagner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transl Res</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="392" to="399" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">C-Terminal Agrin Fragment (CAF) reflects renal function in patients suffering from severe sepsis or septic shock</title>
		<author>
			<persName><forename type="first">M</forename><surname>Drey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Behnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lepiorz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hettwer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bollheimer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Lab</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="69" to="76" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">The ability of agrin to cluster AChRs depends on alternative splicing and on cell surface proteoglycans</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ferns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Campanelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Hoch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Scheller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Hall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuron</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="491" to="502" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Effects of purified recombinant neural and muscle agrin on skeletal muscle fibers in vivo</title>
		<author>
			<persName><forename type="first">G</forename><surname>Bezakova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Helm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Francolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lømo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Biol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="1441" to="1452" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Specific proteolytic cleavage of agrin regulates maturation of the neuromuscular junction</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Bolliger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zurlinden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lüscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bütikofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Shakhova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Francolini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Sci</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="3944" to="3955" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Muscle agrin: neural regulation and localization at nerve-induced acetylcholine receptor clusters</title>
		<author>
			<persName><forename type="first">E</forename><surname>Lieth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Fallon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="2509" to="2514" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Regulation of turnover and number of acetylcholine receptors at neuromuscular junctions</title>
		<author>
			<persName><forename type="first">G</forename><surname>Fumagalli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Balbi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cangiano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lømo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuron</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="563" to="569" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Localized bioimpedance analysis in the evaluation of neuromuscular disease</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Rutkove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Aaron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Shiffman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="390" to="397" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Multifrequency bioelectrical impedance analysis for assessing fat mass and fat-free mass in stroke or transient ischaemic attack patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Kafri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Potter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Myint</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="677" to="682" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Availability and use of dual energy X-ray absorptiometry (DXA) and bioimpedance analysis (BIA) for the evaluation of sarcopenia by Belgian and Latin American geriatricians</title>
		<author>
			<persName><forename type="first">E</forename><surname>Treviño-Aguirre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>López-Teros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gutiérrez-Robledo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vandewoude</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pérez-Zepeda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="79" to="81" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Comparison of three bioelectrical impedance methods with DXA in overweight and obese men</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">R</forename><surname>Pateyjohns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Brinkworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Buckley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Noakes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Clifton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Obesity (Silver Spring)</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="2064" to="2070" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Estimation of skeletal muscle mass by bioelectrical impedance analysis</title>
		<author>
			<persName><forename type="first">I</forename><surname>Janssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Heymsfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Baumgartner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ross</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Appl Physiol</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="465" to="471" />
			<date type="published" when="1985">1985. 2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Assessing skeletal muscle mass: historical overview and state of the art</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Heymsfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Adamek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Thomas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="9" to="18" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Bioelectrical impedance analysis during acute changes of extracellular osmolality in man</title>
		<author>
			<persName><forename type="first">K</forename><surname>Berneis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Keller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="361" to="366" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
